Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.
- Published In:
- Diabetes, obesity & metabolism, 20(4), 889-897 (2018)
- Authors:
- Vilsbøll, Tina(11), Bain, Stephen C(9), Leiter, Lawrence A(4), Lingvay, Ildiko, Matthews, David, Simó, Rafael, Helmark, Ida Carøe, Wijayasinghe, Nelun, Larsen, Michael
- Database ID:
- RPEP-03965
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03965APA
Vilsbøll, Tina; Bain, Stephen C; Leiter, Lawrence A; Lingvay, Ildiko; Matthews, David; Simó, Rafael; Helmark, Ida Carøe; Wijayasinghe, Nelun; Larsen, Michael. (2018). Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.. Diabetes, obesity & metabolism, 20(4), 889-897. https://doi.org/10.1111/dom.13172
MLA
Vilsbøll, Tina, et al. "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.." Diabetes, 2018. https://doi.org/10.1111/dom.13172
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide, reduction in glycated haemoglobin and the risk ..." RPEP-03965. Retrieved from https://rethinkpeptides.com/research/vilsboll-2018-semaglutide-reduction-in-glycated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.